Login

I cannot remember my username

Technology Profits Confidential

The world of tech and biotechnology will provide endless opportunity for growth and wealth for investors who know where to look.

Technology Profits Confidential is your one-stop shop for the companies of tomorrow's technology... and how you can profit from them.

Flash Sell: Book 250% Gains Right Now

Ray Blanco
By Ray BlancoPosted February 21, 2020

Space tourism hit a new milestone. A new space ship is ready for testing in the Mojave desert. And your open position has gone parabolic. Let’s grab these gains while we still can…

You Must Be A Subscriber To View This Content.

If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication(s) below and get access today!

Technology Profits Confidential

With new technologies in mobile computing, biotechnology and 3-D printing, it’s nearly impossible to keep up with the throngs of new innovation and still be able to forecast which companies are set to profit. Technology Profits Confidential is your one-stop shop for the companies of tomorrow’s technology… and how you can profit from them.

Login

Ray Blanco’s VIP Tech Advantage

LoginGet Access

Ray Blanco

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, FDA Profit Alert, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco

Related Posts

Latest Pick on Track to Profit Despite Delays

Ray Blanco
By Ray BlancoPosted March 21, 2014

I've been busy working on your next issue. The company I've identified pioneers a technology that exposes it to multiple high-growth products and markets that are revolutionary in themselves. But without the technology this company specializes in, they won't go anywhere. I'll have much more information for you soon. Our latest pick has achieved some clarity regarding an important event. As you know, new drugs can't be sold in major markets without regulatory approval, and in the world's largest health care market, the gateway is guarded by the FDA.

TOPICS | , , , ,

Tech Companies Showcase Innovations at CES

Ray Blanco
By Ray BlancoPosted January 11, 2013

January is a busy time for technology and biotechnology companies. During the early weeks of the year, tech companies show off their latest innovations at the Consumer Electronics Show in Las Vegas. Biotech companies, on the other hand, engage investors at what is likely the year's largest biotech investor event -- the JP Morgan Healthcare Conference. I'm reviewing those presentations in the hunt for the next great biotechnology investment.

TOPICS | , , , ,

And Then There Were Two…

Ray Blanco
By Ray BlancoPosted December 19, 2014

Up until now, this company has been a “one hit wonder.” It's a biotech company with a single drug in development. It's an important drug, though, one for treating a rare genetic disorder. It's in the late stages, where a flurry of paperwork is submitted to regulatory authorities for marketing approval and the Washington deciders decide. Right now, it's a waiting game in both Europe and the U.S.

TOPICS | , ,

Biotech Bonanza of 2012

Ray Blanco
By Ray BlancoPosted September 7, 2012

So far, 2012 has been a terrific year for our biotechnology portfolio. It's been great for biotech investors in general, despite the weak global economy. The NASDAQ Biotechnology Index (NBI), for example, is up 35%. Our newsletter's biotech picks, however, have outperformed even these stellar returns. Of the stocks we picked before January of this year, the average year to date return has been 58%. If we include our new picks, the figure comes out to 44.8%, year to date.

TOPICS | , , , ,